Establishment Labs has appointed Taylor Harris to its Board of Directors. Mr. Harris brings more than 25 years of experience in corporate finance, executive leadership and board governance across healthcare, medical technology and life sciences companies. He most recently served as Chief Executive Officer of Cutera, and previously was Chief Financial Officer of MyoKardia, where he helped guide the company through its acquisition by Bristol Myers Squibb in a transaction valued at $13.1 billion. He also served as CFO of Zeltiq Aesthetics through its acquisition by Allergan and as CFO of Thoratec Corporation through its acquisition by St. Jude Medical. Chairman Nick Lewin said Mr. Harris's deep expertise in the medical aesthetics industry and his track record of creating substantial value will be a tremendous asset as Establishment Labs becomes a leader in the global aesthetics market.
Establishment Labs Holdings IncAppointment of experienced board member with track record of value creation in medical aesthetics.
Bristol-Myers Squibb Company
Procept Biorobotics Corp